CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 536,295	$ 608,628
Marketable securities	4,325	4,550
Accounts receivable, net of allowances of $0 at March 31, 2020 and December 31, 2019	0	295
Prepaid expenses	17,315	21,818
Other current assets	3,788	3,413
Total current assets	561,723	638,704
Property and equipment, net of accumulated depreciation and amortization of $8,907 and $7,925 at March 31, 2020 and December 31, 2019, respectively	32,150	32,762
Other long-term assets	233	256
Total Assets	594,106	671,722
Current Liabilities:
Accounts payable and accrued expenses	59,268	60,860
Liability related to sale of future royalties - current	7,491	3,455
Lease liability - current	346	337
Convertible senior notes, net	0	7,106
Total current liabilities	67,105	71,758
Liability related to sale of future royalties - non-current	267,215	257,769
Deferred revenues	65,000	65,000
Lease liability - non-current	9,875	9,965
Total Liabilities	409,195	404,492
Commitments and Contingencies (Note 11)
Stockholders' Equity:
Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at March 31, 2020 and December 31, 2019	0	0
Common stock, $0.01 par value; authorized 250,000,000 shares; issued 213,929,505 shares and outstanding 213,809,884 shares at March 31, 2020; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019	2,139	2,125
Capital contributed in excess of par	1,590,185	1,579,205
Treasury stock, at cost: 119,621 shares at March 31, 2020 and December 31, 2019	(2,095)	(2,095)
Accumulated deficit	(1,403,453)	(1,310,406)
Accumulated other comprehensive loss	(802)	(568)
Total Immunomedics, Inc. stockholders' equity	185,974	268,261
Noncontrolling interest in subsidiary	(1,063)	(1,031)
Total Stockholders' Equity	184,911	267,230
Total Liabilities and Stockholders' Equity	$ 594,106	$ 671,722